Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

New York, New York--(Newsfile Corp. - September 8, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Bayer Aktiengesellschaft ("Bayer" or the "Company") (OTC Pink: BAYRY) (OTC Pink: BAYZF) of the September 14, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Bayer Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 In Bayer Aktiengesellschaft To Contact The Firm

Los Angeles, California--(Newsfile Corp. - September 8, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bayer Aktiengesellschaft (OTC Pink: BAYRY) (OTC Pink: BAYZF) ("Bayer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S.

MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bayer Aktiengesellschaft and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

WHIPPANY, N.J.--(BUSINESS WIRE)--Data from Bayer’s evolving oncology portfolio will be presented at the ESMO Virtual Congress 2020, taking place September 19-21, 2020.

 Bayer to Showcase New Data from Evolving Oncology Portfolio at ESMO Virtual Congress 2020

WHIPPANY, N.J.--(BUSINESS WIRE)--REPLACE Study ERS

Bayer Phase IV Study Met its Primary Endpoint in PAH Patients Who Had Transitioned to Adempas® (riociguat) After Insufficient Response to PDE5 Inhibitors

New York, New York--(Newsfile Corp. - September 4, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Bayer Aktiengesellschaft (OTC: BAYRY, BAYZF) between May 23, 2016 and March 19, 2019, inclusive (the "Class Period"), of the important September 14, 2020 lead plaintiff deadline in the securities class action.

ROSEN, NATIONAL TRIAL LAWYERS, Reminds Bayer Aktiengesellschaft Investors of Important Deadline in Securities Class Action - BAYRY, BAYZF

Bayer AG has asked California's Supreme Court to review a decision awarding $20.5 million to a groundskeeper who claimed the company's Roundup weedkiller caused his cancer, arguing the ruling was at odds with federal law and settled legal principles.

Bayer appeals $20.5 million Roundup ruling to California Supreme Court

Bayer is reportedly buying 70% of the direct-to-consumer startup.

Bayer Agrees To Buy Personalized Vitamin Company Care/of At $225 Million Valuation

Bayer (BAYRY) submits a regulatory application seeking approval for vericiguat to treat patients with symptomatic chronic heart failure in China.

Bayer Submits Application for Heart Failure Drug in China

NEW YORK, Aug. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Bayer Aktiengesellschaft (OTC: BAYRY, BAYZF) between May 23, 2016 and March 19, 2019, inclusive (the "Class Period"), of the important September 14, 2020 lead.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Reminds Bayer Aktiengesellschaft Investors of Important Deadline in Securities Class Action - BAYRY, BAYZF

Biogen

Intel

Altria

Merck

Philip Morris

Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating).

Wide Moat Stocks On Sale - The September 2020 Heat Map

German drugs company Bayer AG said on Thursday there were "bumps" in sealing its $11 billion settlement of thousands of U.S. lawsuits over its Roundup weed killer after a U.S.

Bayer acknowledges 'bumps' in $11 billion Roundup deal after judge raises doubts

German drugs company Bayer AG's $11 billion settlement of thousands of U.S. lawsuits over its Roundup weed killer is less defined than the company disclosed, a judge overseeing the suits said, Bloomberg News reported on Thursday.

Bayer-Roundup $11 billion deal at risk of collapse, judge says: Bloomberg News

LEVERKUSEN, Germany & AUSTIN, Texas--(BUSINESS WIRE)--Triumvira Immunologics Inc. (“Triumvira”), a privately-held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, successfully completed a USD $55 million Series A financing round.

 Bayer and Northpond Ventures Lead USD $55 Million Series A Financing Round for Triumvira Immunologics

Bayer said on Thursday it will pay around $1.6 billion to settle the majority of U.S. claims involving its Essure birth-control device.

Bayer to pay $1.6 billion to resolve U.S. suits for Essure birth-control device

LEVERKUSEN, Germany--(BUSINESS WIRE)--Bayer announced today that it has reached agreements with plaintiff law firms to resolve approximately 90% of the nearly 39,000 total filed and unfiled U.S. Essure™ claims involving women who allege device-related injuries.

Bayer Announces Resolution of U.S. Essure™ Claims

NEW YORK, Aug. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Bayer Aktiengesellschaft (OTC: BAYRY, BAYZF) between May 23, 2016 and March 19, 2019, inclusive (the "Class Period"), of the important September 14, 2020 lead.

ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Reminds Bayer Aktiengesellschaft Investors of Important Deadline in Securities Class Action - BAYRY, BAYZF

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

In addition to enhancing Bayer's network efficacies, Verizon (VZ) is likely to enable a seamless and cost-effective network management to help realize its full potential.

Verizon (VZ) to Augment Bayer's Global Network Capabilities

LEVERKUSEN, Germany & SINGAPORE--(BUSINESS WIRE)--Leaps by Bayer, the impact investment arm of Bayer AG and Temasek, the global investment company headquartered in Singapore, today announced the joint investment and formation of a new company, Unfold. The new venture will focus on innovation in vegetable varieties with the goal of lifting the vertical farming space to the next level of quality, efficiency and sustainability.

Bayer and Temasek Unveil Innovative New Company Focused on Developing Breakthroughs in Vertical Farming

The pharmaceutical giant made a big bet on the future of women's healthcare.

Bayer Buys KaNDy Therapeutics for $425 Million Up Front

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer®, a leader in women’s healthcare, and KaNDy Therapeutics Ltd, a UK clinical-stage biotech company, announced today that Bayer will acquire KaNDy Therapeutics Ltd.

Bayer to Acquire UK-Based Biotech KaNDy Therapeutics Ltd.

WHIPPANY, N.J.--(BUSINESS WIRE)--Lori Moore, former Managing Director at Deloitte, will be joining Bayer as Vice President, Head of Pharmaceutical Communications in the United States, the company announced today.

Bayer Names Lori Moore as Vice President, Head of U.S. Pharmaceutical Communications

Bayer: Many Upside Catalysts But The Litigation Risks Weigh More Heavily

WHIPPANY, N.J.--(BUSINESS WIRE)--Building on its more than 50-year commitment to women’s healthcare, today Bayer launched the We’re for Her initiative, which includes a partnership with the humanitarian organization Direct Relief that will help break down barriers so more women across the United States can access contraceptives and make powerful decisions about their families and their futures with the help of a healthcare provider.

Bayer and Direct Relief Team Up to Help Remove Barriers So More Women Can Gain Access to Contraceptives

Werner Enterprises

Bayer Aktiengesellschaft (BAYZF) CEO Werner Baumann on Q2 2020 Results - Earnings Call Transcript

Bayer's (BAYRY) earnings and sales fall year over year in the second quarter of 2020.

News for Bayer AG Stock (BAYRY)